title: Focus on: Neuroscience and treatment: the potential of neuroscience to inform treatment.
abstract: In the 40 years since the founding of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), researchers have gained a better understanding of the brain circuits and brain chemical (i.e., neurotransmitter) systems involved in the development and maintenance of alcoholism and other drug dependence. This understanding has led to the identification of numerous potential targets for pharmacotherapy of addiction. For example, insight into the roles of signaling molecules called endogenous opioids and the neurotransmitter glutamate were fundamental for developing two medications--naltrexone and acamprosate--now used in the treatment of alcoholism. However, the processes of dependence development (e.g., reinforcement, sensitization, and withdrawal) are highly complex and involve a plethora of contributing influences, which also may differ from patient to patient. Therefore, existing pharmacotherapies still are effective only for some but not all alcoholic patients. Accordingly, researchers are continuing to explore the processes involved in addiction development to identify new targets for treatment and develop new medications that can address different aspects of the dependence syndrome, thereby increasing the likelihood of successful treatment. NIAAA continues to play a pivotal role in funding and conducting this research in order to provide effective treatment options to millions of alcohol-dependent patients.
authors.affiliation: Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego, San Diego, California.
authors.forename: George F
authors.initials: GF
authors.lastname: Koob
mesh_terms: D000427:Alcohol Deterrents / Q000008:administration & dosage; D000437:Alcoholism / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D000818:Animals; D035843:Biomedical Research / Q000639:trends*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D006801:Humans; D009292:Narcotic Antagonists / Q000008:administration & dosage; D054563:National Institute on Alcohol Abuse and Alcoholism (U.S.) / Q000639:trends*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
chemical_list: D000427:Alcohol Deterrents; D009292:Narcotic Antagonists